Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?

As of 20 February 2018, the valuation grade for Ultragenyx Pharmaceutical, Inc. moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued, given its high Price to Book Value of 24.36 and negative EV to EBITDA of -8.10, alongside a troubling ROE of -377.52%. In comparison to its peers, Madrigal Pharmaceuticals has a significantly worse P/E ratio of -35.88, while Corcept Therapeutics is categorized as very expensive with a P/E of 60.03, highlighting the relative valuation challenges Ultragenyx faces. The company's stock has underperformed against the S&P 500 across multiple periods, with a staggering YTD return of -30.81% compared to the index's 12.22%. This trend of underperformance reinforces the notion that Ultragenyx is currently overvalued in the market.